A multinational drugmaker is paying 45 states including South Dakota $105 million to settle complaints that the company unlawfully marketed three drugs.
South Dakota Attorney General Marty Jackley says South Dakota's share of the settlement is nearly $1.2 million.
The settlement resolves allegations that London-based Glaxo illegally marketed Advair, Paxil and Wellbutrin for purposes that had not been approved by the Food and Drug Administration. Once the FDA approves a drug as safe and effective, a manufacturer cannot market or promote that drug for an unapproved use, a practice called off-label marketing.
The asthma treatment Advair is Glaxo's best-selling product. Paxil and Wellbutrin are antidepressant drugs.